New joint guidance for clinicians on migraine prevention was released by the American Headache Society and the American Academy of Neurology. The groups had last updated their recommendations in 2012. Authors noted that many new preventive options have reached the market since that time, prompting this comprehensive update. The guideline text is available through the published DOI cited by the authors.
The recommendations advise clinicians to offer preventive therapy to people experiencing at least four migraine or severe headache days per month, or to patients whose migraine attacks substantially interfere with their ability to work or perform daily tasks. The article also notes that many eligible patients are unaware that preventive treatments are an option.
The guidance provides working definitions used in the recommendations. Chronic migraine is defined as headache on 15 or more days per month for over three months, with at least eight of those days including the features of a migraine (for example, severe pain lasting hours to days, nausea, aura, photosensitivity, or phonophobia). The guidelines include separate recommendations for less frequent, episodic migraines and for chronic migraine.
A prominent update is the inclusion and favorable assessment of newer therapies that target the calcitonin gene–related peptide (CGRP) pathway. The article lists several agents that received high marks for efficacy and tolerability: atogepant (Qulipta), eptinezumab (Vyepti), erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality). These agents were also recommended as options for patients who frequently rely on acute pain medications at the time of attacks. The guidance notes that some patients experience reduced headache frequency after tapering down overuse of acute medications.
The guideline continues to highlight established preventive options with longer safety records. For chronic migraine, botulinum toxin (Botox) is noted as well tolerated in the studies reviewed. For episodic migraine, propranolol is cited. The anticonvulsant topiramate is included as an effective preventive medication; the article emphasizes that these older treatments have more extensive long-term safety data compared with newer agents.
Clinicians are advised to evaluate how well a preventive therapy is working after 8 to 12 weeks of use. This time frame is presented as the practical interval for determining early response and guiding decisions to continue, switch, or escalate therapy.
The guideline presents tailored recommendations for different patient subgroups, including people with high body mass index, those with fibromyalgia, patients with hypertension, and those who might be pregnant. The article reports that recommendations were sorted based on priorities such as efficacy, tolerability, and long-term safety when creating guidance for these subgroups.
The authors and external commentators noted potential conflicts between the guideline statements and other specialty recommendations. For example, the guideline’s discussion of the tricyclic antidepressant amitriptyline as a feasible option in some pregnant patients contradicts guidance from the American College of Obstetricians and Gynecologists, which advises against tricyclic antidepressants during pregnancy because of risks cited by that organization. Similarly, topiramate is recommended as an option and as potentially helpful in patients with high BMI but is also associated with birth defects and reduced efficacy of hormonal contraception at higher doses—factors clinicians must weigh when choosing treatment.
The report highlights several areas where the guideline’s recommendations could complicate real-world prescribing. Some medications commonly used in practice received more limited endorsements in the guidance despite existing evidence and affordability. The angiotensin receptor blocker candesartan, often used off-label for migraine prevention in the U.S. and Europe and considered well tolerated and inexpensive, was rated as having “insufficient evidence to support its use.” Likewise, the CGRP-blocking oral agent rimegepant (Nurtec)—approved in 2021 as a preventive for episodic migraine—was recommended only after higher-evidence options are tried.
Experts quoted in the article warned that multilayered qualification criteria in guidelines can provide payers with reasons to deny coverage. They argued that tiered recommendations and additional required steps may hinder patient access to effective therapies, especially when payers use guideline complexity to justify prior-authorization denials.
The process to update the guidance began in January 2018. The writing panel included 19 headache specialists and researchers from the U.S. and several experts from Canada. About one-third of the panel had relevant conflicts of interest; those panelists were not allowed to rate or review evidence but did participate in voting on the recommendations. The article states that conflict-free authors led the development of the guidelines.
Commentators in the article stressed that guidelines can strengthen clinicians’ positions when requesting coverage from payers by providing authoritative recommendations, but real-world outcomes will depend on patients’ ability to seek and afford care. The authors and external experts expressed concern that complexity in recommendations and differences between specialty guidance could complicate prescribing decisions and contribute to payer resistance. The article further reiterates that an estimated 15% of Americans experience migraines, with women disproportionately affected, underscoring the public-health relevance of the updated guidance.